Gilead Sciences, Inc. GILD
Gilead Sciences, Inc. (Nasdaq: GILD) is an oncology drug developer. Its lead program, anito-cel (anitocabtagene autoleucel), is in Phase 3 for relapsed or refractory multiple myeloma (4L+).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Biktarvy | HIV treatment | small molecule | Approved |
| Descovy | HIV treatment | small molecule | Approved |
| Genvoya | HIV treatment | small molecule | Approved |
| Trodelvy | triple-negative breast cancer, first-line | antibody | Approved |
| Hepcludex | chronic hepatitis delta virus | protein/peptide | Approved |
| Livdelzi | chronic liver disease | small molecule | Approved |
| Veklury | COVID-19 | small molecule | Approved |
| Tecartus | relapsed or refractory mantle cell lymphoma | cell therapy | Approved |
| Yescarta | relapsed or refractory large B-cell lymphoma | cell therapy | Approved |
| anito-cel | relapsed or refractory multiple myeloma | cell therapy | Phase 3 |
| Yeztugo | HIV pre-exposure prophylaxis (PrEP), once-weekly oral | small molecule | Phase 3 |
| TUB-040 | oncology | antibody | Pre-clinical |
Recent results and decisions
- Oct 29, 2026approval FDA approved Bixlenvo for the treatment of HIV in virologically suppressed adults.
Received U.S. Food and Drug Administration ("FDA") approval for Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg) for the treatment of HIV in adults who are virologically suppressed on a stable antiretroviral regimen.
Filing - Oct 29, 2026approval European Commission approved Trodelvy in combination with Keytruda for first-line mTNBC with PD-L1 CPS≥10.
Announced European Commission ("EC") marketing authorization for Trodelvy in combination with Keytruda® (pembrolizumab) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer ("mTNBC") who have not received prior systemic therapy for metast
Filing - Oct 29, 2026met Emvistegrast 200mg met its primary endpoint of clinical response at Week 12 in the Phase 2 SWIFT study in ulcerative colitis.
Emvistegrast 200mg met its primary endpoint of clinical response at Week 12, with a generally well-tolerated safety profile.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
- Summit Therapeutics Inc. SMMT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.